These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 26871551

  • 1. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.
    Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ, Chao YM, Liu NC, Chan JY.
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [Abstract] [Full Text] [Related]

  • 3. Protective Effect of Combined Caffeic Acid Phenethyl Ester and Bevacizumab Against Hydrogen Peroxide-Induced Oxidative Stress in Human RPE Cells.
    Dinc E, Ayaz L, Kurt AH.
    Curr Eye Res; 2017 Dec; 42(12):1659-1666. PubMed ID: 28937872
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 6. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E, Ayaz L, Kurt AH.
    J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
    [Abstract] [Full Text] [Related]

  • 7. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB, Rho CR, Shin JA, Lyu J, Kang S.
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [Abstract] [Full Text] [Related]

  • 8. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA, Abedi S, Schneider K, Chwa M, Kenney MC.
    Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
    [Abstract] [Full Text] [Related]

  • 9. Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.
    De Cillà S, Farruggio S, Vujosevic S, Raina G, Filippini D, Gatti V, Clemente N, Mary D, Vezzola D, Casini G, Rossetti L, Grossini E.
    Cell Physiol Biochem; 2017 Dec; 42(5):1725-1738. PubMed ID: 28743128
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 11. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
    Dithmer M, Hattermann K, Pomarius P, Aboul Naga SH, Meyer T, Mentlein R, Roider J, Klettner A.
    Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L, Fuhrer R, Zinkernagel M, Enzmann V.
    Ophthalmologica; 2019 Apr; 241(3):137-142. PubMed ID: 30001546
    [Abstract] [Full Text] [Related]

  • 13. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Eur J Ophthalmol; 2016 Aug 04; 26(5):425-30. PubMed ID: 27079208
    [Abstract] [Full Text] [Related]

  • 14. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, Kuppermann BD.
    Br J Ophthalmol; 2014 Jun 04; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [Abstract] [Full Text] [Related]

  • 15. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L, Roider J, Klettner A.
    Ophthalmic Res; 2021 Jun 04; 64(3):369-388. PubMed ID: 33011724
    [Abstract] [Full Text] [Related]

  • 16. Effects of Bevacizumab on Bcl-2 Expression and Apoptosis in Retinal Pigment Epithelial Cells under Oxidative Stress.
    Kim S, Kim YJ, Kim NR, Chin HS.
    Korean J Ophthalmol; 2015 Dec 04; 29(6):424-32. PubMed ID: 26635460
    [Abstract] [Full Text] [Related]

  • 17. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
    Bahrami B, Shen W, Zhu L, Zhang T, Chang A, Gillies MC.
    Clin Exp Ophthalmol; 2019 Nov 04; 47(8):1074-1081. PubMed ID: 31265210
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of risuteganib and bevacizumab on AMD cybrid cells.
    Schneider K, Chwa M, Atilano SR, Shao Z, Park J, Karageozian H, Karageozian V, Kenney MC.
    Exp Eye Res; 2021 Feb 04; 203():108287. PubMed ID: 33075294
    [Abstract] [Full Text] [Related]

  • 19. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.
    Angiogenesis; 2016 Jul 04; 19(3):389-406. PubMed ID: 27234973
    [Abstract] [Full Text] [Related]

  • 20. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium.
    Im S, Song MH, Elangovan M, Woo KM, Park WJ.
    Sci Rep; 2024 Jun 17; 14(1):13920. PubMed ID: 38886213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.